Diseases & Disorders
(G46Z)
IRS Verified
DX Registered
990 on File
CELIAC DISEASE FOUNDATION
Financial strength (30%)
80/100
Reliability (20%)
55/100
Effectiveness (25%)
71/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
Celiac disease is one of the world’s most prevalent genetic autoimmune diseases, affecting an estimated 3 million Americans, 70-80% of whom are undiagnosed. Causing the body to attack its own small intestine, it can lead to many other devastating health conditions, including cancer. Unfortunately for the millions who suffer, celiac disease has largely been ignored by our federal government which provides little to no funding for research nor for public awareness of its serious consequences. Through strategic investments in research, education, and advocacy, the Celiac Disease Foundation seeks to remedy this by accelerating treatments and a cure.
Financial Overview — FY 2025
$5.3M
Total Revenue
$4.6M
Total Expenses
$6.8M
Net Assets
18
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
69.6%
Fundraising Efficiency
250.3%
Operating Reserve
17.89x
Liability-to-Asset
17.7%
Revenue Diversification
48.3%
Executive Compensation
$760K
Compared with Peers
FY 2025
Compared with 336 similar organizations
(United States, Diseases & Disorders, $1M–$10M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
69.6% | 82.1% |
P10P90
|
Bottom quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
17.3% | 11.1% |
P10P90
|
Bottom quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
13.1% | 3.1% |
P10P90
|
Bottom quarter |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
250.3% | 114.8% |
P10P90
|
Below median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
17.9 mo | 12.8 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
17.7% | 12.5% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
48.3% | 87.6% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
23.8% | 6.7% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
5.6% | 6.5% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
13.8% | 3.9% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $5.3M | $4.6M | $6.8M | 69.6% | 18 |
| 2024 | $4.3M | $4.3M | $5.6M | 75.4% | 18 |
| 2023 | $4.2M | $3.0M | $5.3M | 81.7% | 14 |
| 2022 | $3.1M | $2.2M | $3.9M | 75.4% | 11 |
| 2021 | $4.7M | $2.1M | N/A | — | 10 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.